Bioventus Inc - A · Q4 2020 earnings

Briefing

Reported financial results for the fourth quarter and year ended December 31, 2020.

Bioventus Inc. reported Q4 2020 net sales of $98.6 million, a 1% increase year-over-year. The company's net income from continuing operations was $2.3 million. Adjusted EBITDA was $28.2 million, down 8% year-over-year.

• Net sales increased by 1% year-over-year, reaching $98.6 million.
• U.S. net sales increased by 3% year-over-year to $89.7 million, while international net sales decreased by 17% year-over-year to $8.9 million.
• Net income from continuing operations decreased by 58% year-over-year to $2.3 million.
• Adjusted EBITDA decreased by 8% year-over-year to $28.2 million.

Headline financials

Revenue & EPS history

For the twelve months ending December 31, 2021, the Company expects net sales of $360 million to $372 million, net income attributable to common shareholders of $15 million to $19 million, Non-GAAP net income attributable to common shareholders of $43 million to $46 million, and Adjusted EBITDA of $79 million to $83 million.